Colposcopy News and Research

RSS

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Cervical cancer diagnosis is a two-step process. In developed countries, women are invited for a smear test which mainly uses LBC (liquid-based cytology), where a sample of cells are taken from the cervix and sent to a cytopathology lab for analysis.

From Zilico 19 Mar 2014

Researchers complete genomic analysis of cervical cancer in two patient populations

Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.

25 Dec 2013

Hologic's Aptima HPV 16 18/45 genotype assay gets FDA approval for use on Panther system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration has approved the Aptima HPV 16 18/45 genotype assay for use on the Company's fully automated Panther system.

From Hologic, Inc. 8 Nov 2013

Age-old practice of annual screening exams for cervical cancer may be harmful than helpful

For decades, women between the ages of 21 and 69 were advised to get annual screening exams for cervical cancer. In 2009, however, accumulating scientific evidence led major guideline groups to agree on a new recommendation that women be screened less frequently: every three years rather than annually.

10 Jul 2013

Study shows very few physicians follow HPV and cervical cancer prevention guidelines

Recent breakthroughs in cervical cancer prevention have resulted in new vaccination and cervical cancer screening guidelines. Recommendations do not always translate into practice, however.

9 Jul 2013

Early detection methods can help cure cervical cancer

Cervical cancer, a disease that will affect more than 12,000 women in the United States this year and more than a half million women worldwide, leads to significantly fewer deaths when effective early detection methods are available, either via a Pap smear or with a test for presence of the human papilloma virus.

4 Jun 2013

Sexual revolution effect may be hiding true extent of HPV prevalence

Human papillomavirus infection in older women is commonly due to reactivation of latent disease rather than new infection, research indicates.

2 Jan 2013

Guided Therapeutics files amended PMA with FDA for LuViva Advanced Cervical Scan

Guided Therapeutics, Inc., today announced that it has submitted its premarket approval (PMA) Amendment for the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, instantly and at the point of care.

13 Nov 2012

FDA approves Hologic’s APTIMA HPV 16 18/45 Genotype Assay for use on TIGRIS system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's APTIMA HPV 16 18/45 Genotype Assay for use on its TIGRIS instrument system.

From Hologic, Inc. 16 Oct 2012

Quest Diagnostics announces availability of TERC test for cervical cancer

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory test that identifies molecular changes to cervical cells that increase the likelihood a woman may develop cervical cancer.

From Quest Diagnostics 31 Aug 2012

Cervical cancer screening: an interview with Alastair Atkinson, CEO of DySIS Medical Ltd

Cervical Cancer is a tragic disease. First and foremost, because it is entirely preventable if the early symptoms are detected in a timely manner

20 Aug 2012

Cervical cancer screening product from DySIS Medical recommended by NICE

DySIS Medical Ltd, the medical devices company in female health, announces that the National Institute for Health and Clinical Excellence (‘NICE’) has today published positive diagnostics guidance recommending its DySIS cervical cancer screening product to be considered in procurement plans.

1 Aug 2012

Guided Therapeutics seeks premarket approval from FDA for LuViva Advanced Cervical Scan

Guided Therapeutics, Inc. today announced that it met with the Food and Drug Administration (FDA) on July 20, 2012. The company believes the meeting was very positive and plans to work with FDA to finalize the path forward to gain premarket approval (PMA) for the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, instantly and at the point of care.

26 Jul 2012

CAP/ASCCP LAST Project recommendations for better diagnosis of HPV-associated lesions

The College of American Pathologists (CAP) and the American Society for Colposcopy and Cervical Pathology (ASCCP) jointly issued The Lower Anogenital Squamous Terminology (LAST) Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations.

4 Jul 2012

New guidelines on cervical cancer screening

Many women over the last few decades have gone in for their Pap smear tests each year. Now, two influential groups of medical experts say that having cervical cancer screening once a year is not necessary and, in fact, should be discouraged. Many women can wait as long as five years between screenings, the new guidelines say.

15 Mar 2012

Colposcopy News and Research

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Researchers complete genomic analysis of cervical cancer in two patient populations

Hologic's Aptima HPV 16 18/45 genotype assay gets FDA approval for use on Panther system

Age-old practice of annual screening exams for cervical cancer may be harmful than helpful

Study shows very few physicians follow HPV and cervical cancer prevention guidelines

Early detection methods can help cure cervical cancer

Sexual revolution effect may be hiding true extent of HPV prevalence

Guided Therapeutics files amended PMA with FDA for LuViva Advanced Cervical Scan

FDA approves Hologic’s APTIMA HPV 16 18/45 Genotype Assay for use on TIGRIS system

Quest Diagnostics announces availability of TERC test for cervical cancer

Cervical cancer screening: an interview with Alastair Atkinson, CEO of DySIS Medical Ltd

Cervical cancer screening product from DySIS Medical recommended by NICE

Guided Therapeutics seeks premarket approval from FDA for LuViva Advanced Cervical Scan

CAP/ASCCP LAST Project recommendations for better diagnosis of HPV-associated lesions

New guidelines on cervical cancer screening

ACS, ASCCP and ASCP release new screening guidelines for cervical cancer

HPV and smear tests offer more effective approach for cervical screening

Guided Therapeutics seeks CE Mark approval for LuViva Advanced Cervical Scan

Polarized filter may improve ability to detect precancerous changes, reduce unnecessary biopsies

New guidelines for prevention and early detection of cervical cancer

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Bridging the Gap between Academia and Industry: The Power of Collaboration in Life Sciences

Revolutionizing Schizophrenia Research

Latest News